Cardiovascular · Clinical trials
Hypertension Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About hypertension — and why its trials are hard
Hypertension is chronically elevated arterial blood pressure and the single largest modifiable risk factor for stroke, myocardial infarction, heart failure and chronic kidney disease. Contemporary guidelines (ACC/AHA, ESC/ESH) define stage 1 hypertension at systolic 130-139 or diastolic 80-89 mmHg and emphasize confirmed out-of-office measurement plus staged pharmacotherapy. First-line agents are thiazide/thiazide-like diuretics, ACE inhibitors, angiotensin-receptor blockers (ARBs) and dihydropyridine calcium-channel blockers, typically combined to reach target. Most large outcome trials predate strict endpoint-magnitude reporting, but the drug-class benefit on cardiovascular events is firmly established. A genuinely novel mechanism arrived in March 2024 when the FDA approved aprocitentan (Tryvio), a dual endothelin-A/B receptor antagonist, for resistant/uncontrolled hypertension based on the PRECISION trial. Resistant hypertension, defined as uncontrolled pressure despite three agents including a diuretic, remains a major unmet need, and endothelin blockade addresses a pathway not covered by renin-angiotensin drugs. Fluid retention and edema are the principal class limitations. Lifestyle modification underpins every step of management.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Aprocitentan (Tryvio) | 2024 | Resistant/uncontrolled hypertension, add-on | PRECISION | Change in office systolic BP at week 4 | Placebo-corrected office SBP reduction of ~3.7-3.8 mmHg at week 4 (aprocitentan 12.5 and 25 mg); ~4 mmHg on ambulatory SBP |
| Lisinopril (ACE inhibitor class) (Prinivil/Zestril) | 1987 | First-line hypertension | ALLHAT (class outcome trial) | Fatal CHD or nonfatal MI | No difference in primary CHD endpoint vs chlorthalidone; thiazide superior for some secondary CV outcomes (unverified precise HR) |
| Amlodipine (dihydropyridine CCB) (Norvasc) | 1992 | First-line hypertension | ALLHAT / ASCOT-BPLA | Composite CV events / fatal CHD or nonfatal MI | ASCOT-BPLA: amlodipine-based regimen reduced all-cause mortality and stroke vs atenolol-based (unverified precise HR) |
| Losartan (ARB class) (Cozaar) | 1995 | First-line hypertension, esp. with LVH | LIFE | Composite CV death, MI, stroke | ~13% relative risk reduction vs atenolol at similar BP; driven by stroke reduction (unverified exact HR) |
| Chlorthalidone (thiazide-like diuretic) (generic) | approved pre-1980 | First-line hypertension | ALLHAT / SHEP | Fatal CHD/nonfatal MI; stroke (SHEP) | SHEP: ~36% reduction in stroke in isolated systolic hypertension (unverified exact figure) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in hypertension development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Darusentan — DORADO / DORADO-AC | Failed to meet co-primary office BP endpoints in resistant hypertension in the controlled program despite earlier signal | Fluid retention/edema, inconsistent office vs ambulatory BP effects; selective endothelin-A antagonism did not translate to durable controlled benefit |
| Aliskiren — ALTITUDE | Stopped early for lack of benefit and signals of harm (hyperkalemia, hypotension, renal events) when added to ACE inhibitor/ARB in diabetics | Dual renin-angiotensin blockade caused excess adverse events; led to contraindication of combination in diabetes |
Choosing the right endpoint
Primary endpoints that matter in hypertension trials
- Office systolic blood pressure change — Primary surrogate in most modern antihypertensive trials, including PRECISION week-4 endpoint
- 24-hour ambulatory BP — Key confirmatory measure reducing white-coat effect; used as secondary endpoint in PRECISION
- Major adverse cardiovascular events (MACE) — Composite of CV death, MI, stroke used in class outcome trials such as LIFE and ASCOT
- Stroke incidence — Most BP-sensitive hard outcome; drove benefit in SHEP and LIFE
How iNGENū runs hypertension trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Hypertension clinical trials — FAQs
What makes aprocitentan different from existing drugs?
Are ACE inhibitors and ARBs used together?
What is resistant hypertension?
Ready to discuss your hypertension trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal